Status:

COMPLETED

A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases

Lead Sponsor:

Pfizer

Conditions:

Acute Bronchitis

Eligibility:

All Genders

16-80 years

Phase:

PHASE3

Brief Summary

To evaluate the clinical efficacy and safety in patients with Acute Bronchitis or Secondary Infection of Chronic Respiratory Diseases receiving a dose of 2 g of azithromycin in the SR formulation.

Eligibility Criteria

Inclusion

  • Patients who were diagnosed as mild or moderate in severity by the classification of infection of the Japanese Society of Chemotherapy guidelines for the evaluation methods of new antibacterial drug (established in 1997).

Exclusion

  • Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2007

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT00360464

Start Date

October 1 2006

End Date

June 1 2007

Last Update

April 21 2011

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

Pfizer Investigational Site

Hitachi-Naka, Ibaraki, Japan, 312-0057

2

Pfizer Investigational Site

Kasama, Ibaraki, Japan, 309-1793

3

Pfizer Investigational Site

Moriya, Ibaraki, Japan, 302-0118

4

Pfizer Investigational Site

Toride, Ibaraki, Japan, 302-0005